NCCN VERSION 2 2015

153 / 188

Version 2.2015, 03/11/15 © National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. MS-78
NCCN Guidelines Index
Breast Cancer Table of Contents
Discussion
NCCN Guidelines Version 2.2015
Breast Cancer
Clin Oncol 1998;16:2672-2685. Available at:
158. Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or
postoperative docetaxel added to preoperative doxorubicin plus
cyclophosphamide for operable breast cancer:National Surgical
Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol
2006;24:2019-2027. Available at:
.
159. Hudis C, Modi S. Preoperative chemotherapy for breast cancer:
miracle or mirage? JAMA 2007;298:2665-2667. Available at:
.
160. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher
pathologic complete remission rate after neoadjuvant therapy with
trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a
randomized trial in human epidermal growth factor receptor 2-positive
operable breast cancer. J Clin Oncol 2005;23:3676-3685. Available at:
.
161. Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with
paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide
chemotherapy and concurrent trastuzumab in human epidermal growth
factor receptor 2-positive operable breast cancer: an update of the initial
randomized study population and data of additional patients treated with
the same regimen. Clin Cancer Res 2007;13:228-233. Available at:
.
162. Untch M, Loibl S, Bischoff J, et al. Lapatinib versus trastuzumab in
combination with neoadjuvant anthracycline-taxane-based
chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Lancet Oncol 2012;13:135-144. Available at:
.
163. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with
trastuzumab for HER2-positive early breast cancer (NeoALTTO): a
randomised, open-label, multicentre, phase 3 trial. Lancet
2012;379:633-640. Available at:
.
164. Piccart-Gebhart M, Holmes A, de Azambuja E, et al. The
association between event-free survival and pathological complete
response to neoadjuvant lapatinib, trastuzumab or their combination in
HER2-positive breast cancer. Survival follow-up analysis of the
NeoALTTO study (BIG 1-06). [abstract]. Program and abstracts of the
2013 San Antonio Breast Cancer Symposium; December 10-14, 2013;
San Antonio, Texas. :Abstract S1-01. Available at:
df.
165. Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced
antitumor activity of trastuzumab and pertuzumab combination
treatment on HER2-positive human xenograft tumor models. Cancer
Res 2009;69:9330-9336. Available at:
.
166. Baselga J, Cortes J, Im S-A, et al. Biomarker analyses in
CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in
HER2-positive, first-line metastatic breast cancer (MBC). Cancer
Research 2012;72:S5-1. Available at:
eetingAbstracts/S5-1.
167. Swain S, Kim S-B, Cortes J, et al. Confirmatory overall survival
(OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-
controlled Phase III study with pertuzumab (P), trastuzumab (T), and
docetaxel (D) in patients (pts) with HER2-positive first-line (1L)
metastatic breast cancer (MBC). Cancer Research 2012;72:P5-18-26.
Available at:
eetingAbstracts/P5-18-26.
168. Schneeweiss A, Chia S, Hickish T, et al. Pertuzumab plus
trastuzumab in combination with standard neoadjuvant anthracycline-
containing and anthracycline-free chemotherapy regimens in patients